Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Anticancer Activity of Metallodrugs
View:
Post by Oden6570 on Jul 31, 2024 7:55am

Anticancer Activity of Metallodrugs

7.2.3. Polypyridyl Ru(II) Complexes as Photosensitisers (PS) in Photodynamic Therapy (PDT) Polypyridyl-type Ru(II) complexes, whether coordination complexes or organometallic complexes, have properties that make them suitable for use in PDT applications. Photodynamic therapy is a therapeutic technique approved for the treatment of cancer that aims to exert its action in a localised manner while reducing side effects. The basis of this therapy is based on the use of a molecule capable of being activated by light, called photosensitiser visible light and molecular oxygen [183]. Photodynamic therapy consists of two steps: first, the PS is administered so that it accumulates in the cancerous tissues and, in the second step, it is exposed to light. These two independent steps reduce side effects because the photosensitiser, which is non-toxic in the dark, is only activated when irradiated with light that is concentrated on the specific area where the tumour is located, destroying it. This is a Int. J. Mol. Sci. 2024, 25, 7314 27 of 45 way of reducing side effects as the PS only acts on the irradiated area and not on healthy tissue [184]. Some polypyridyl-type Ru(II) complexes may act as agents for teragnosis, as they can exert a therapeutic function, act as a photosensitiser of PDT, and as a bioimaging agent for diagnosis [185]. The TLD-1433 complex, described by S. McFarland’s research group, 2020, is the first Ru(II)-based photosensitiser for photodynamic therapy to enter human clinical trials for the treatment of muscle-invasive bladder cancer
Anticancer-Curieses_et_al-2024-IJMS.pdf
Comment by Tarbaby on Jul 31, 2024 10:41am
Good analysis.. But you did not mention that the NEW PDT is Xray PDT. The xrays turn into photons deep in a body to trigger the drug to kill cancer....Its a New ball game...huge future coming. Check out Fox Chase clinical trial using xrays for PDT. Munster University in Germany has an xray Pdt trial going also. Plus a few others. But none have Rutherrin...we do.
Comment by stocksnbonds458 on Jul 31, 2024 3:56pm
Xrays ARE photons, they are high energy photons (or high frequency light waves if you like).They dont "turn" into photons. They may certainly lose energy as they pass through tissue though, and in doing so be reduced to microwaves or some other lower energy/lower frequency component of the light spectrum
Comment by Tarbaby on Jul 31, 2024 7:32pm
I believe the xray photons have some interactions in the body that creates  blue wavelength light. That may be what triggers the Rutherrin to create radical oxygen molecules which destroy the cancer cells. It isn t the xrays themselves destroying the csncer although they may help to weaken it. I believe they just use short bursts of xrays not continuous radiation. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250